{"gene":"RARG","run_date":"2026-06-10T06:43:36","timeline":{"discoveries":[{"year":1995,"finding":"Crystal structure of the RARγ ligand-binding domain (LBD) bound to all-trans retinoic acid at 2.0 Å resolution reveals ligand-binding interactions and a 'mouse trap' mechanism: ligand binding induces a conformational transition that repositions the C-terminal amphipathic alpha-helix (AF-2 activating domain) to form a transcriptionally active receptor, sealing the ligand pocket.","method":"X-ray crystallography (2.0 Å resolution crystal structure)","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — atomic-resolution crystal structure with mechanistic interpretation, foundational study widely replicated","pmids":["7501014"],"is_preprint":false},{"year":1997,"finding":"Purification of human RARγ LBD (residues 178–423) and determination that its Kd for all-trans retinoic acid is 0.6 ± 0.1 nM; crystals of the LBD–ligand complex were grown and confirmed to diffract to 2.0 Å.","method":"Recombinant protein purification (E. coli), ligand-binding assay, X-ray crystallography","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with quantitative binding measurement and structural validation","pmids":["9016769"],"is_preprint":false},{"year":2002,"finding":"1.4 Å crystal structure of RARγ LBD complexed with retinoid SR11254 reveals multiple C-H…O hydrogen bonds between the ligand hydroxyl and the hydrophobic ligand pocket, providing a structural basis for receptor-subtype selectivity and affinity.","method":"X-ray crystallography (1.4 Å resolution)","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 / Strong — high-resolution crystal structure with direct structural analysis of ligand interactions","pmids":["12220491"],"is_preprint":false},{"year":1992,"finding":"RARγ2 expression is autoregulated through a retinoic acid response element (RARE) in its own promoter, consisting of a 6-bp direct repeat with a 5-nucleotide spacer; this RARE is bound most effectively by RAR/RXR heterodimers, and Sp1 binding sites flanking the RARE synergistically enhance RARγ2 promoter activity.","method":"Reporter gene assays, cotransfection, mutational analysis of RARE, EMSA (receptor binding to RARE)","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (reporter assays, mutagenesis, binding assays) in a single rigorous study","pmids":["1320193"],"is_preprint":false},{"year":1995,"finding":"Targeted disruption of RARγ in F9 embryonal carcinoma cells specifically impairs RA-induced expression of Hoxa-1, Hoxa-3, laminin B1, collagen IV (α1), GATA-4, and BMP-2, and reduces metabolism of all-trans-RA to polar derivatives, demonstrating that RARγ regulates a distinct subset of RA target genes and RA metabolism.","method":"Homologous recombination knockout, RT-PCR/Northern blot for target gene expression, RA metabolism assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean knockout with multiple target gene readouts and metabolic assay, replicated across labs","pmids":["7823950"],"is_preprint":false},{"year":1995,"finding":"RAR-RXR heterodimers require activation of both partners for synergistic induction of RA-responsive endogenous genes and differentiation of P19 and F9 cells; RARγ-selective retinoids combined with RXR-selective retinoids synergistically induce differentiation, demonstrating functional redundancy between RARα, RARβ, and RARγ in this context.","method":"Selective synthetic retinoids in cell-based differentiation assays, gene expression analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — systematic pharmacological dissection with isoform-selective ligands across multiple endpoints and cell lines","pmids":["8524212"],"is_preprint":false},{"year":1995,"finding":"Reexpression of RARγ2 in RARγ-null F9 cells restores both RA-target gene activation (Cdx1, Gap43, Stra4, Stra6) and differentiation potential; overexpression of RARα can partially substitute, but RARβ overexpression only poorly restores differentiation, establishing partial functional redundancy between RAR subtypes with RARγ as the primary mediator of differentiation.","method":"Stable rescue cell lines, RT-PCR for target gene expression, morphological differentiation assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic rescue with isoform-specific re-expression, multiple orthogonal readouts, complementary to knockout study","pmids":["7644503"],"is_preprint":false},{"year":1997,"finding":"Phosphorylation of both AF-1 and AF-2 activation functions of RARγ2 is required for RA-induced primitive endodermal differentiation of F9 cells; AF-1 phosphorylation at the proline-directed kinase site of RARγ2 is specifically required for primitive endoderm, while parietal differentiation additionally requires RARα1 AF-1 phosphorylation and PKA-site phosphorylation of RARα AF-2.","method":"Phosphorylation site mutagenesis, stable cell lines in RARγ-null F9 cells, differentiation assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis of specific phosphorylation sites with functional rescue, multiple isoforms tested","pmids":["9351827"],"is_preprint":false},{"year":2002,"finding":"Upon RA binding, RARγ2 undergoes proteasome-dependent degradation signaled through both AF-1 (phosphorylated by p38MAPK) and AF-2 (via recruitment of SUG-1, a component of the 19S regulatory subunit of the 26S proteasome); blocking either p38MAPK or proteasome function impairs RARγ2 transactivation activity, linking receptor turnover to transcriptional activation.","method":"Pharmacological inhibition of p38MAPK and proteasome, co-immunoprecipitation of SUG-1, mutagenesis of AF-1/AF-2, reporter gene assays, pulse-chase degradation assay","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (Co-IP, mutagenesis, kinase inhibition, reporter assays, protein stability assay) in single rigorous study","pmids":["12110588"],"is_preprint":false},{"year":2003,"finding":"RARγ2 is the 'engine' of the RAR heterodimer driving both transcription and its own proteasomal degradation after ligand binding; integrity of its AF-2 domain and phosphorylation of its AF-1 domain are required for both degradation and transactivation; RXRα plays a modulatory/cooperative role through its own AF-1 (phosphorylated) and AF-2 domains.","method":"Domain deletion mutants, AF-1 phosphorylation site mutants, transfection assays, ubiquitin-proteasome pathway analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — systematic mutagenesis of both heterodimer partners with multiple functional readouts","pmids":["12824162"],"is_preprint":false},{"year":2005,"finding":"Vinexin β, a SH3 motif-containing cytoskeletal protein, interacts with the non-phosphorylated AF-1 domain of RARγ (but not RARα or RARβ); upon phosphorylation of AF-1, vinexin β dissociates. Vinexin β colocalizes with RARγ in the nucleus and functions as a repressor of RARγ-mediated transcription, as demonstrated by overexpression and RNAi knockdown.","method":"Yeast two-hybrid, co-immunoprecipitation, immunofluorescence colocalization, stable overexpression, siRNA knockdown, reporter assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal protein interaction confirmed by yeast two-hybrid and Co-IP, localization data, and functional assays with both gain- and loss-of-function","pmids":["15734736"],"is_preprint":false},{"year":2015,"finding":"A nonsynonymous coding variant in RARG (rs2229774, p.Ser427Leu) is associated with anthracycline-induced cardiotoxicity; this variant alters RARG function, leading to derepression of TOP2B (topoisomerase 2β), which is a key genetic determinant of anthracycline-induced cardiotoxicity.","method":"GWAS with functional validation: reporter/expression assays showing derepression of TOP2B by RARG S427L variant","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — GWAS discovery with functional validation, replicated in three independent cohorts, mechanistic pathway identified","pmids":["26237429"],"is_preprint":false},{"year":2021,"finding":"The RARG S427L variant (rs2229774) mediates increased doxorubicin-induced cardiotoxicity by suppressing TOP2B expression and failing to activate the cardioprotective ERK pathway; the RARγ agonist CD1530 attenuates doxorubicin-induced cardiotoxicity in patient-specific hiPSC-CMs and in vivo mouse models.","method":"Patient-specific hiPSC-CMs, CRISPR isogenic lines, molecular pathway analysis (ERK, TOP2B), in vivo mouse DIC model, pharmacological rescue","journal":"Cell stem cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — isogenic CRISPR lines with mechanistic pathway dissection validated in vivo, multiple orthogonal methods","pmids":["34525346"],"is_preprint":false},{"year":2020,"finding":"CRISPR/Cas9 correction of RARG-S427L to wild type reduces doxorubicin-induced double-stranded DNA breaks, ROS production, and cell death in iPSC-CMs; introduction of S427L increases susceptibility; genetic disruption of RARG protects from doxorubicin-induced cell death, establishing a direct causal role for RARG S427L in DIC.","method":"CRISPR/Cas9 isogenic iPSC-CM lines, cell viability, optical mapping, DNA damage (γH2AX), ROS assays","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — isogenic CRISPR knockin/correction with multiple cellular readouts, bidirectional genetic manipulation","pmids":["32587261"],"is_preprint":false},{"year":2022,"finding":"RARG p.S427L variant leads to reduced activation of RARG target genes (including DNA repair pathways) in response to doxorubicin in iPSC-CMs, resulting in impaired DNA repair; molecular dynamic simulations predict structural changes confirmed by gene expression studies.","method":"Molecular dynamic simulations, CRISPR-edited iPSC-CMs, RNA-Seq, DNA damage assays","journal":"Stem cell reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — CRISPR isogenic lines with RNA-Seq, structural prediction validated functionally; single lab with multiple orthogonal methods","pmids":["35364012"],"is_preprint":false},{"year":2022,"finding":"ATRA activates RARγ, induces interferon-β response and IRF1 expression; IRF1 initiates transcription of OAS1, which synthesizes 2-5A to activate RNase L and cause RNA degradation and cell death, thereby sensitizing multiple myeloma cells to carfilzomib; selective RARγ agonist BMS961 recapitulates this effect.","method":"High-throughput drug screen, selective RARγ agonist, gene knockdown, reporter assays, in vivo myeloma model","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and genetic dissection of pathway in vitro and in vivo, but full mechanistic reconstitution not reported; single lab","pmids":["34411225"],"is_preprint":false},{"year":2006,"finding":"RARγ is selectively expressed in primitive hematopoietic precursors; RARγ knockout mice show markedly reduced HSC numbers with increased mature progenitors; overexpression of RARγ (but not RARα) in primitive precursors maintains an undifferentiated phenotype; pharmacological RARγ activation promotes HSC self-renewal as shown by serial transplant studies.","method":"RARγ knockout mice, competitive transplantation, retroviral overexpression, ex vivo culture with selective agonists, serial transplant","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function, gain-of-function, and pharmacological approaches with quantitative cellular readouts and serial transplant validation","pmids":["16682494"],"is_preprint":false},{"year":2011,"finding":"In embryonic stem cells, RARγ (in the absence of ligand RA) is required for deposition of the histone variant H2A.Z and polycomb group protein Suz12 at RA target gene loci; RARγ and Suz12 exist in a multi-protein complex in the absence of ligand. Upon RA addition, H2A.Z and Suz12 are removed from these loci concurrent with transcriptional activation.","method":"ChIP, co-immunoprecipitation, RARγ-null ES cells","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and ChIP in null ES cells; single lab, two orthogonal methods","pmids":["20857416"],"is_preprint":false},{"year":2012,"finding":"RARγ is required for RA-induced chromatin remodeling (H3K9/K14ac increase at proximal promoters) and transcriptional activation of a subset of RA target genes (e.g., Meis1, Lrat, Stra6, Crabp2, Cyp26a1) in embryonic stem cells; H3K4me3 at Meis1 proximal promoter does not require RARγ, revealing gene-specific epigenetic requirements.","method":"RARγ knockout ES cells, RNA-Seq/RT-PCR, ChIP for H3K9/K14ac and H3K4me3","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic null cells with genome-wide transcriptome and locus-specific ChIP, multiple chromatin marks analyzed","pmids":["23264745"],"is_preprint":false},{"year":2003,"finding":"In Cyp26a1-null mice, ectopic RA signaling in the tail bud is mediated specifically by RARγ; activated RARγ downregulates Wnt3a and Fgf8. Genetic ablation of Rarg rescues Cyp26a1-null mice from caudal regression and embryonic lethality, demonstrating that CYP26A1 suppresses RARγ-mediated downregulation of WNT3A and FGF8 signaling pathways.","method":"Compound Cyp26a1/Rarg double knockout mice, in situ hybridization for Wnt3a and Fgf8, embryo survival analysis","journal":"Development","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with double knockout rescue and downstream pathway gene expression analysis","pmids":["12588859"],"is_preprint":false},{"year":2009,"finding":"TNIP1 acts as an atypical corepressor of agonist-bound RARα and RARγ: it requires NR boxes, ligand, and the receptor's AF-2 domain for interaction (properties characteristic of coactivators), yet represses RAR activity; repression is partially relieved by SRC1; preferential interaction of RARα over RARγ maps to helices 5–9 of the RARα LBD.","method":"Co-immunoprecipitation, deletion/domain mutants, reporter gene assays, competitive binding with SRC1","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP with domain mapping and functional reporter assays, single lab","pmids":["19732752"],"is_preprint":false},{"year":2017,"finding":"Cytoplasmic RARγ controls RIP1-initiated apoptosis and necroptosis when cIAP activity is blocked downstream of TNF receptor 1; RARγ mediates RIP1 dissociation from TNFR1, initiating cytosolic death complex (complex II/necrosome) formation. In response to cIAP inhibition, RARγ is released from the nucleus to orchestrate formation of cytosolic death complexes.","method":"shRNA library screen, RARγ knockdown/knockout, co-immunoprecipitation of TNFR1-RIP1 complex, subcellular fractionation, in vivo TNF-induced necroptosis model","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic screen validation, Co-IP of signaling complex, subcellular localization, in vivo confirmation","pmids":["28871172"],"is_preprint":false},{"year":2014,"finding":"RARγ2 is engaged in active transcriptional repression (via co-repressor complex) throughout axial elongation in Xenopus, not only as a terminator; in the absence of RA, unliganded RARγ2 represses caudal progenitor genes to maintain the progenitor pool; upon RA, RARγ2 switches to activator, facilitating somite differentiation. Dominant-negative co-repressor or VP16-RARγ2 overexpression prematurely terminates axis elongation.","method":"Dominant-negative RARγ overexpression, selective RARγ inverse agonist (NRX205099) and agonist (NRX204647), dominant-negative co-repressor (c-SMRT), Xenopus embryo in vivo assays, in situ hybridization","journal":"Development","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic and pharmacological tools with in vivo readouts in Xenopus","pmids":["24821986"],"is_preprint":false},{"year":2014,"finding":"NUP98-RARG fusion protein acquires nuclear localization patterns and transcriptional properties similar to RARA fusions; its oncogenic transformation of hematopoietic stem/progenitor cells depends on the C-terminal GLFG domain of NUP98 and the DNA-binding domain of RARG; NUP98-RARG homodimerizes and recruits both RXRA and wild-type NUP98; transformed cells are sensitive to ATRA.","method":"Murine bone marrow retroviral transduction/transformation assay, domain deletion mutants, nuclear localization imaging, reporter gene assays, Co-IP","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 2 / Strong — systematic mutagenesis in transformation assay, Co-IP of protein complex, multiple orthogonal functional readouts","pmids":["25510432"],"is_preprint":false},{"year":2016,"finding":"RARγ promotes phosphorylation of Lats1 and Yap binding to Lats1, thereby inactivating Yap target gene expression and suppressing colorectal cancer; knockdown of RARγ activates Hippo-Yap oncogenic signaling, driving cancer cell growth, invasion, and metastasis.","method":"RARγ knockdown, Co-IP of Lats1-Yap, phosphorylation assays, in vitro invasion assays, in vivo xenograft","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP/phosphorylation data with in vitro and in vivo functional readouts; single lab","pmids":["27325643"],"is_preprint":false},{"year":2024,"finding":"In macrophages, RARγ interacts with TRAF6 and prevents TRAF6 oligomerization and autoubiquitination, thereby inhibiting NF-κB signaling; tumor-derived lactate drives H3K18 lactylation to suppress RARγ gene transcription, releasing TRAF6 to promote IL-6/STAT3 signaling. NDGA directly binds RARγ to inhibit TRAF6-IL-6-STAT3 axis.","method":"Co-immunoprecipitation of RARγ-TRAF6, chromatin modification analysis (H3K18 lactylation ChIP), TRAF6 ubiquitination assays, direct binding assay (NDGA-RARγ), in vivo colorectal cancer models","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, ubiquitination assay, chromatin modification ChIP, and direct ligand binding with in vivo validation","pmids":["38245869"],"is_preprint":false},{"year":2025,"finding":"CPSF6-RARG fusion (CR) interacts with HDAC3 to suppress expression of myeloid differentiation genes including PU.1; disrupting the CR-HDAC3 interaction restores PU.1 expression and myeloid differentiation; HDAC inhibitors suppress CR-driven leukemia in vitro and in vivo.","method":"Co-immunoprecipitation of CR-HDAC3, gene expression analysis, HDAC inhibitor treatment, in vivo leukemia model","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP establishing physical complex, functional rescue by disruption of interaction, in vivo validation","pmids":["39805830"],"is_preprint":false},{"year":2025,"finding":"RARG fusions disrupt myeloid differentiation and promote HSPC proliferation/self-renewal by upregulating BCL2 and ATF3; co-occurrence with heterozygous Wt1 loss induces fully penetrant AML by activating MYC and HOXA9/MEIS1 targets; all RARG-aAPL cases harbor tripartite X::RARG::X fusions with truncation of LBD helix 11–12, which is mechanistically responsible for ATRA unresponsiveness through protein allosteric dysfunction.","method":"Retroviral transduction/transformation assays, RNA-Seq, molecular structure analysis, high-throughput drug screening (Connectivity Map)","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo leukemia model, transcriptomic pathway dissection, structural analysis, genetic epistasis (Wt1 loss), validated in 21 RARG-aAPL cases","pmids":["39805831"],"is_preprint":false},{"year":2024,"finding":"All RARG-aAPL cases harbor tripartite X::RARG::Y fusion transcripts with RARG 3' splice consistently at the terminus of exon 9, resulting in LBD helix 11–12 truncation; this truncation (not present in artificially mimicked bipartite fusions) drives ATRA unresponsiveness and leukemogenesis through protein allosteric dysfunction.","method":"Molecular investigation of fusion transcripts in 21 RARG-aAPL cases, protein structural analysis, experimental functional assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — systematic molecular characterization with structural analysis and experimental validation across 21 patient cases","pmids":["39046762"],"is_preprint":false},{"year":2013,"finding":"CDK1 interacts with RARγ in the nucleus; RARγ regulates CDK1 protein levels and its subcellular localization in response to ATRA; CDK1 is required for optimal ATRA effect in U-937 leukemic cells and modulates P27(kip) and AKT phosphorylation; CDK1 and RARγ form a reciprocal regulatory circuit influencing each other's protein stability.","method":"Co-immunoprecipitation, subcellular fractionation, CDK1 inhibition, immunofluorescence, Western blot in leukemia cells","journal":"Cell cycle","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP with functional correlates, single lab","pmids":["23518499"],"is_preprint":false},{"year":2014,"finding":"In ATRA-inhibited adipocyte differentiation, RARγ (but not RARα) interacts with C-Fos protein; this interaction inhibits C-Fos DNA binding activity at the PPARγ2 promoter, reducing PPARγ2 expression and blocking adipocyte differentiation; RARγ inhibitor blocks ATRA-induced reduction of C-Fos binding to PPARγ2 promoter.","method":"Co-immunoprecipitation of RARγ-C-Fos, chromatin immunoprecipitation (ChIP) for C-Fos at PPARγ2 promoter, RARγ inhibitor, Western blot","journal":"Biochimie","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and ChIP with pharmacological inhibitor validation, single lab","pmids":["25173565"],"is_preprint":false},{"year":2022,"finding":"RARγ binds to and stimulates genes responsible for Akt dephosphorylation in satellite cells, inhibiting overall protein translation initiation to maintain quiescence; alleviation of retinoic acid signaling releases satellite cells from quiescence; this restraint is lost in aged cells.","method":"ChIP for RARγ occupancy at target genes, in vivo satellite cell activation assays, RA signaling inhibition, aged vs. young muscle comparison","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP with functional in vivo readouts; single lab, mechanistic pathway partially established","pmids":["36175396"],"is_preprint":false},{"year":2018,"finding":"miR-96 directly targets RARγ mRNA to downregulate RARγ expression; reduced RARγ levels (independent of exogenous retinoid) impact prostate cell viability; RARγ cistrome is enriched at active enhancers associated with AR binding sites, and RARγ knockdown significantly alters the magnitude of the AR transcriptome.","method":"miR-96 mimic/biotin-miR-96 targetome capture, luciferase 3'UTR reporter assay, ChIP-Seq (RARγ cistrome), shRNA knockdown, RNA-Seq","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct targetome capture and luciferase validation, ChIP-Seq cistrome; single lab","pmids":["30120411"],"is_preprint":false},{"year":2022,"finding":"A synthetic retinoid induces RARγ translocation from the nucleus to the cytoplasm; nuclear RARγ normally binds the Cdc42 promoter; cytoplasmic translocation reduces RARγ-Cdc42 promoter binding, downregulating Cdc42, decreasing F-actin, and inhibiting cytoskeletal tension, leading to chromatin decondensation and DNA damage in tumor-repopulating cells.","method":"Immunofluorescence/live imaging for RARγ translocation, ChIP for RARγ at Cdc42 promoter, Cdc42/F-actin rescue experiments, tumor-repopulating cell apoptosis assay","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and imaging with rescue experiments; single lab, mechanistic chain partially validated","pmids":["36031407"],"is_preprint":false},{"year":2004,"finding":"Ligation of RARγ (but not RARα) by selective agonists inhibits proliferation of PHA-stimulated T cells by preventing IL-2-induced upregulation of JAK3 protein levels (without affecting JAK1), thereby inhibiting STAT5 phosphorylation and Rb phosphorylation.","method":"Selective RARγ agonists, RARγ antagonist, Western blot for JAK1/JAK3/STAT5/Rb, T cell proliferation assay","journal":"Immunology letters","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — pharmacological approach with isoform-selective compounds, multiple signaling readouts; single lab","pmids":["15790515"],"is_preprint":false},{"year":2004,"finding":"In IP-12-7 T cells, RA induces nur77 expression and DNA binding, and FasL cell surface appearance via RARγ; two RARγ-selective compounds (CD437 and CD2325) initiate apoptosis while natural RA cannot, because natural RA-liganded RARγ cannot sensitize the Fas death pathway even though it induces FasL expression.","method":"Selective RAR agonists/antagonists, EMSA for nur77 DNA binding, flow cytometry for FasL surface expression, apoptosis assays","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — pharmacological approach with receptor-selective ligands and multiple readouts; single lab","pmids":["14991612"],"is_preprint":false},{"year":2001,"finding":"RARγ and Cdx1 interact synergistically in vertebral patterning: compound RARγ-Cdx1 double null mutants show increased severity of cervical homeotic transformations relative to single nulls; exogenous RA requires Cdx1 for full vertebral morphogenetic effects, placing RARγ upstream of Cdx1 in axial patterning while also indicating parallel pathways converging on common targets.","method":"Compound null mouse genetics, skeletal phenotype analysis, RA treatment of compound nulls","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — complete allelic series with genetic epistasis analysis, RA treatment of multiple genotypes","pmids":["11784046"],"is_preprint":false},{"year":2000,"finding":"The conserved amphipathic alpha-helical core motif (helix 12) of RARγ AF-2 is required for RA-induced differentiation of F9 cells and RA target gene expression; AF-2 deletion mutants of RARγ2 and RARα1 behave as dominant negatives, blocking differentiation.","method":"Stable cell lines expressing AF-2 deletion mutants in RARγ-null F9 cells, differentiation assays, target gene expression analysis","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 1 / Moderate — structure-function mutagenesis with clear dominant-negative phenotype; single lab but mechanistically definitive","pmids":["10910773"],"is_preprint":false},{"year":2018,"finding":"Combinatorial knockout of all three RAR isoforms (RARα, RARβ, RARγ) by CRISPR completely abrogates all transcriptional responses to RA in murine embryonic stem cells, demonstrating that the transcriptional effects of RA are entirely RAR-dependent with no RAR-independent transcriptional route.","method":"CRISPR biallelic knockout of all three RARs, RNA-Seq transcriptome analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — complete genetic ablation of all three RARs with genome-wide transcriptome readout; definitive result","pmids":["29848550"],"is_preprint":false}],"current_model":"RARγ is a ligand-activated nuclear receptor that, upon all-trans retinoic acid binding, undergoes a 'mouse trap' conformational change repositioning the AF-2/helix-12 to form an active transcriptional complex; its AF-1 domain is phosphorylated by p38MAPK, enabling dissociation of the corepressor vinexin β and recruitment of SUG-1 (19S proteasome subunit) to drive coupled transcriptional activation and proteasomal degradation; as a heterodimer with RXRα, it binds RAREs to regulate a distinct subset of RA target genes (including Hoxa-1, Cdx1, Meis1, Stra6, TOP2B) via epigenetic mechanisms (H2A.Z/Suz12 deposition in ground state; H3K9/K14ac induction upon activation); it also operates as a cytoplasmic signaling scaffold (released from nucleus to mediate RIP1-initiated TNF death complex formation) and interacts with partners including TRAF6 (inhibiting NF-κB), CDK1, C-Fos, and HDAC3 (in RARG fusion leukemia); a coding variant (S427L) reduces RARγ activity, derepresses TOP2B, and increases anthracycline cardiotoxicity; RARG fusion proteins in AML acquire LBD helix 11–12 truncations that render them ATRA-unresponsive and leukemogenic through allosteric dysfunction and HDAC3 recruitment."},"narrative":{"mechanistic_narrative":"RARγ is a ligand-activated nuclear receptor that, as a heterodimer with RXRα bound to retinoic acid response elements, transduces all-trans retinoic acid (RA) signals into transcriptional programs governing cellular differentiation, axial patterning, and stem cell fate [PMID:1320193, PMID:8524212, PMID:29848550]. Atomic-resolution structures of its ligand-binding domain established the 'mouse trap' mechanism, in which RA binding repositions the C-terminal AF-2 helix-12 to seal the ligand pocket and create a transcriptionally active surface [PMID:7501014, PMID:9016769]; integrity of this AF-2 helix is obligatory for RA-induced differentiation, and AF-2 deletions act as dominant negatives [PMID:10910773]. Productive transactivation additionally requires p38MAPK phosphorylation of the AF-1 domain, which both releases the corepressor vinexin β and couples receptor turnover to activation through recruitment of the 19S proteasome subunit SUG-1 [PMID:12110588, PMID:12824162, PMID:15734736]. RARγ controls a distinct subset of RA target genes (Hoxa-1, Cdx1, Stra6, Meis1, Cyp26a1) and the differentiation of embryonal carcinoma and embryonic stem cells, acting through epigenetic switching: in the unliganded state it nucleates an H2A.Z/Suz12 repressive configuration that is replaced by H3K9/K14 acetylation upon ligand-driven activation [PMID:7823950, PMID:7644503, PMID:20857416, PMID:23264745]. In vivo it is the dominant RAR mediator of caudal axial patterning, restraining Wnt3a and Fgf8 to terminate axis elongation, and it maintains hematopoietic stem cell self-renewal and satellite-cell quiescence [PMID:12588859, PMID:24821986, PMID:16682494, PMID:36175396]. Beyond the nucleus, RARγ functions as a cytoplasmic signaling scaffold: it is released from the nucleus to drive RIP1-dependent TNFR1 death-complex assembly, and it restrains inflammatory signaling by binding TRAF6 to block its oligomerization and NF-κB activation [PMID:28871172, PMID:38245869]. A coding variant (p.Ser427Leu) reduces RARγ activity and derepresses TOP2B, impairing DNA repair and the cardioprotective ERK response to confer anthracycline-induced cardiotoxicity, which is reversed by genetic correction or RARγ agonists [PMID:26237429, PMID:34525346, PMID:32587261, PMID:35364012]. RARG fusion proteins (NUP98-, CPSF6-, and tripartite X::RARG::Y) cause an atypical acute promyelocytic leukemia: consistent truncation of LBD helix 11-12 renders them ATRA-unresponsive, and they recruit HDAC3 to suppress myeloid differentiation genes such as PU.1 [PMID:25510432, PMID:39805830, PMID:39805831, PMID:39046762].","teleology":[{"year":1995,"claim":"Established how ligand binding switches the receptor on at the structural level, defining the activation mechanism for the whole RAR class.","evidence":"2.0 Å crystal structure of the RA-bound RARγ LBD revealing the 'mouse trap' AF-2 helix repositioning","pmids":["7501014","9016769"],"confidence":"High","gaps":["Structure of the full-length heterodimer on DNA not resolved","Does not capture corepressor- or coactivator-bound conformations"]},{"year":1992,"claim":"Showed RARγ acts on RAREs as an RXR heterodimer and is itself autoregulated, anchoring it in the RA transcriptional circuit.","evidence":"Reporter assays, RARE mutagenesis, and EMSA of the RARγ2 promoter","pmids":["1320193"],"confidence":"High","gaps":["Sp1 cooperativity mechanism not detailed at the protein level"]},{"year":1995,"claim":"Defined RARγ as the principal RAR mediating differentiation and a specific subset of RA target genes, distinguishing it functionally from RARα/β.","evidence":"RARγ-null F9 cell knockout and isoform-specific rescue with target gene and differentiation readouts","pmids":["7823950","7644503","8524212"],"confidence":"High","gaps":["Mechanistic basis for isoform target-gene selectivity not resolved","Partial redundancy with RARα leaves unique substrate set incompletely mapped"]},{"year":2000,"claim":"Pinned the differentiation function to the AF-2 helix-12 motif, linking structure to phenotype.","evidence":"AF-2 deletion mutants in RARγ-null F9 cells showing dominant-negative block of differentiation","pmids":["10910773"],"confidence":"High","gaps":["Coactivators recruited via AF-2 in this context not identified"]},{"year":2002,"claim":"Connected receptor activation to phosphorylation and proteasomal turnover, showing transcription and degradation are coupled.","evidence":"p38MAPK and proteasome inhibition, SUG-1 Co-IP, AF-1/AF-2 mutagenesis, and pulse-chase in RARγ2","pmids":["12110588","12824162"],"confidence":"High","gaps":["E3 ligase mediating ubiquitination not identified","Quantitative relationship between turnover rate and output undefined"]},{"year":2005,"claim":"Identified vinexin β as a phospho-regulated, RARγ-specific corepressor, explaining how AF-1 phosphorylation derepresses the receptor.","evidence":"Yeast two-hybrid, reciprocal Co-IP, colocalization, and gain/loss-of-function reporter assays","pmids":["15734736"],"confidence":"High","gaps":["How vinexin β represses transcription mechanistically unclear","Genome-wide targets of this repression not mapped"]},{"year":2006,"claim":"Extended RARγ function to adult stem-cell biology, showing it maintains hematopoietic stem cell self-renewal.","evidence":"RARγ knockout mice, retroviral overexpression, and serial transplantation with selective agonists","pmids":["16682494"],"confidence":"High","gaps":["Transcriptional targets governing self-renewal in HSCs not defined","Whether the same epigenetic switch operates in HSCs untested"]},{"year":2012,"claim":"Revealed RARγ's bimodal epigenetic mechanism: an unliganded H2A.Z/Suz12 repressive state that converts to an H3K9/K14ac active state upon RA.","evidence":"ChIP and Co-IP in RARγ-null ES cells across multiple chromatin marks and RA target loci","pmids":["20857416","23264745"],"confidence":"High","gaps":["Enzymes depositing/removing H2A.Z and Suz12 in this context not identified","Locus-specific rules for chromatin requirement incompletely defined"]},{"year":2003,"claim":"Placed RARγ in vivo as the effector of caudal RA signaling controlling Wnt3a/Fgf8, with developmental epistasis to Cyp26a1.","evidence":"Cyp26a1/Rarg double-knockout rescue with in situ hybridization for Wnt3a/Fgf8","pmids":["12588859","11784046","24821986"],"confidence":"High","gaps":["Direct vs. indirect regulation of Wnt3a/Fgf8 not separated","Corepressor identity sustaining the unliganded repressive state in vivo not defined"]},{"year":2017,"claim":"Revealed a non-genomic role: cytoplasmic RARγ scaffolds RIP1-initiated TNFR1 death complexes, expanding its function beyond transcription.","evidence":"shRNA screen, RARγ knockout, TNFR1-RIP1 Co-IP, subcellular fractionation, and in vivo necroptosis model","pmids":["28871172"],"confidence":"High","gaps":["Signal that triggers nuclear export not defined","Direct binding interface with RIP1/TNFR1 not mapped"]},{"year":2015,"claim":"Linked an RARG coding variant to a human disease phenotype, defining a TOP2B-dependent mechanism of anthracycline cardiotoxicity.","evidence":"GWAS with functional reporter validation showing S427L derepresses TOP2B, replicated in three cohorts","pmids":["26237429"],"confidence":"High","gaps":["How S427L alters receptor conformation/activity not resolved at this stage"]},{"year":2022,"claim":"Established causality and mechanism for S427L cardiotoxicity and demonstrated pharmacological rescue.","evidence":"CRISPR isogenic hiPSC-CMs, RNA-Seq, DNA damage/ROS assays, in vivo mouse model, and agonist rescue (CD1530)","pmids":["32587261","34525346","35364012"],"confidence":"High","gaps":["Direct RARγ targets driving DNA repair impairment not fully enumerated","Clinical translatability of agonist rescue not established"]},{"year":2025,"claim":"Defined the molecular basis of RARG-fusion leukemia: helix 11-12 truncation produces ATRA-unresponsive receptors that recruit HDAC3 to block myeloid differentiation.","evidence":"Fusion characterization in patient cohorts, structural analysis, HDAC3 Co-IP, transformation assays, and HDAC inhibitor rescue in vivo","pmids":["25510432","39805830","39805831","39046762"],"confidence":"High","gaps":["Allosteric mechanism of helix 11-12 truncation not structurally resolved","Full set of differentiation genes silenced by fusion-HDAC3 not mapped"]},{"year":2024,"claim":"Showed RARγ restrains tumor-associated inflammation by sequestering TRAF6, with lactylation-driven silencing releasing the brake.","evidence":"Reciprocal RARγ-TRAF6 Co-IP, TRAF6 ubiquitination assays, H3K18 lactylation ChIP, and in vivo CRC models","pmids":["38245869"],"confidence":"High","gaps":["Whether TRAF6 sequestration is nuclear or cytoplasmic not pinned down","Generality beyond macrophages/CRC untested"]},{"year":2018,"claim":"Demonstrated RA transcriptional output is entirely RAR-dependent, formally bounding the receptor family's role.","evidence":"CRISPR triple knockout of all three RARs with genome-wide RNA-Seq in ES cells","pmids":["29848550"],"confidence":"High","gaps":["Does not partition the RARγ-specific fraction of the transcriptome"]},{"year":null,"claim":"How RARγ partitions between its genomic (RARE/chromatin) and non-genomic (cytoplasmic scaffold) modes, and which signals govern its nuclear export, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of cytoplasmic RARγ complexes","Trigger and machinery for nucleocytoplasmic shuttling undefined","Integration of phosphorylation, turnover, and localization into a unified switch unmapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,3,5,18,38]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[3,32,33]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[0,1,2]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,8]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[21,25]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[10,17,23,29]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[21,33]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[17,18]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,4,18,38]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[19,22,36]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[17,18]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[21,35]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[11,27,28]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[8,9]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[25,34]}],"complexes":["RARγ-RXRα heterodimer","RARγ/Suz12 (PRC2-associated) complex","TNFR1-RIP1 death complex (complex II/necrosome)"],"partners":["RXRA","SUG-1","VINEXIN Β","TRAF6","RIP1","HDAC3","CDK1","SUZ12"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P13631","full_name":"Retinoic acid receptor gamma","aliases":["Nuclear receptor subfamily 1 group B member 3"],"length_aa":454,"mass_kda":50.3,"function":"Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence of ligand, acts mainly as an activator of gene expression due to weak binding to corepressors. Required for limb bud development. In concert with RARA or RARB, required for skeletal growth, matrix homeostasis and growth plate function (By similarity)","subcellular_location":"Nucleus; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P13631/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/RARG","classification":"Not Classified","n_dependent_lines":24,"n_total_lines":1208,"dependency_fraction":0.019867549668874173},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/RARG","total_profiled":1310},"omim":[{"mim_id":"612569","title":"CELL DIVISION CYCLE AND APOPTOSIS REGULATOR 1; CCAR1","url":"https://www.omim.org/entry/612569"},{"mim_id":"612376","title":"ACUTE PROMYELOCYTIC LEUKEMIA; APL","url":"https://www.omim.org/entry/612376"},{"mim_id":"605522","title":"LIMB DEVELOPMENT MEMBRANE PROTEIN 1; LMBR1","url":"https://www.omim.org/entry/605522"},{"mim_id":"605092","title":"PHOSPHOLIPASE A AND ACYLTRANSFERASE 4; PLAAT4","url":"https://www.omim.org/entry/605092"},{"mim_id":"605090","title":"RETINOIC ACID RECEPTOR RESPONDER 1; RARRES1","url":"https://www.omim.org/entry/605090"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"esophagus","ntpm":137.7},{"tissue":"skin 1","ntpm":114.7}],"url":"https://www.proteinatlas.org/search/RARG"},"hgnc":{"alias_symbol":["RARC","NR1B3","RARgamma","RAR-gamma"],"prev_symbol":[]},"alphafold":{"accession":"P13631","domains":[{"cath_id":"3.30.50.10","chopping":"98-158","consensus_level":"high","plddt":94.7646,"start":98,"end":158},{"cath_id":"1.10.565.10","chopping":"183-415","consensus_level":"high","plddt":95.2626,"start":183,"end":415}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P13631","model_url":"https://alphafold.ebi.ac.uk/files/AF-P13631-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P13631-F1-predicted_aligned_error_v6.png","plddt_mean":78.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=RARG","jax_strain_url":"https://www.jax.org/strain/search?query=RARG"},"sequence":{"accession":"P13631","fasta_url":"https://rest.uniprot.org/uniprotkb/P13631.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P13631/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P13631"}},"corpus_meta":[{"pmid":"7501014","id":"PMC_7501014","title":"Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid.","date":"1995","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/7501014","citation_count":965,"is_preprint":false},{"pmid":"26237429","id":"PMC_26237429","title":"A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.","date":"2015","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26237429","citation_count":222,"is_preprint":false},{"pmid":"16682494","id":"PMC_16682494","title":"RARgamma is critical for maintaining a balance between hematopoietic stem cell self-renewal and differentiation.","date":"2006","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16682494","citation_count":168,"is_preprint":false},{"pmid":"7823950","id":"PMC_7823950","title":"Targeted disruption of retinoic acid receptor alpha (RAR alpha) and RAR gamma results in receptor-specific alterations in retinoic acid-mediated differentiation and retinoic acid metabolism.","date":"1995","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7823950","citation_count":152,"is_preprint":false},{"pmid":"8524212","id":"PMC_8524212","title":"Synergistic activation of retinoic acid (RA)-responsive genes and induction of embryonal carcinoma cell differentiation by an RA receptor alpha (RAR alpha)-, RAR beta-, or RAR gamma-selective ligand in combination with a retinoid X receptor-specific ligand.","date":"1995","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8524212","citation_count":141,"is_preprint":false},{"pmid":"12110588","id":"PMC_12110588","title":"Phosphorylation by p38MAPK and recruitment of SUG-1 are required for RA-induced RAR gamma degradation and transactivation.","date":"2002","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/12110588","citation_count":126,"is_preprint":false},{"pmid":"12189556","id":"PMC_12189556","title":"Retinoids cause apoptosis in pancreatic cancer cells via activation of RAR-gamma and altered expression of Bcl-2/Bax.","date":"2002","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12189556","citation_count":119,"is_preprint":false},{"pmid":"38245869","id":"PMC_38245869","title":"Histone lactylation inhibits RARγ expression in macrophages to promote colorectal tumorigenesis through activation of TRAF6-IL-6-STAT3 signaling.","date":"2024","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/38245869","citation_count":116,"is_preprint":false},{"pmid":"1320193","id":"PMC_1320193","title":"RAR gamma 2 expression is regulated through a retinoic acid response element embedded in Sp1 sites.","date":"1992","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/1320193","citation_count":115,"is_preprint":false},{"pmid":"7644503","id":"PMC_7644503","title":"Reexpression of retinoic acid receptor (RAR) gamma or overexpression of RAR alpha or RAR beta in RAR gamma-null F9 cells reveals a partial functional redundancy between the three RAR types.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7644503","citation_count":99,"is_preprint":false},{"pmid":"9351827","id":"PMC_9351827","title":"Phosphorylation of activation functions AF-1 and AF-2 of RAR alpha and RAR gamma is indispensable for differentiation of F9 cells upon retinoic acid and cAMP treatment.","date":"1997","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9351827","citation_count":99,"is_preprint":false},{"pmid":"25947075","id":"PMC_25947075","title":"Attenuation of EMT in RPE cells and subretinal fibrosis by an RAR-γ agonist.","date":"2015","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/25947075","citation_count":71,"is_preprint":false},{"pmid":"12588859","id":"PMC_12588859","title":"Developing with lethal RA levels: genetic ablation of Rarg can restore the viability of mice lacking Cyp26a1.","date":"2003","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/12588859","citation_count":66,"is_preprint":false},{"pmid":"20935257","id":"PMC_20935257","title":"A novel NUP98/RARG gene fusion in acute myeloid leukemia resembling acute promyelocytic leukemia.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20935257","citation_count":66,"is_preprint":false},{"pmid":"34525346","id":"PMC_34525346","title":"RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy.","date":"2021","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/34525346","citation_count":65,"is_preprint":false},{"pmid":"9228081","id":"PMC_9228081","title":"Specific activation of retinoic acid receptors (RARs) and retinoid X receptors reveals a unique role for RARgamma in induction of differentiation and apoptosis of S91 melanoma cells.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9228081","citation_count":62,"is_preprint":false},{"pmid":"12220491","id":"PMC_12220491","title":"C-H...O hydrogen bonds in the nuclear receptor RARgamma--a potential tool for drug selectivity.","date":"2002","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/12220491","citation_count":62,"is_preprint":false},{"pmid":"23264745","id":"PMC_23264745","title":"RARγ is essential for retinoic acid induced chromatin remodeling and transcriptional activation in embryonic stem cells.","date":"2012","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/23264745","citation_count":60,"is_preprint":false},{"pmid":"27325643","id":"PMC_27325643","title":"RARγ Downregulation Contributes to Colorectal Tumorigenesis and Metastasis by Derepressing the Hippo-Yap Pathway.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27325643","citation_count":56,"is_preprint":false},{"pmid":"16455309","id":"PMC_16455309","title":"Characterization of the retinoic acid receptor genes raraa, rarab and rarg during zebrafish development.","date":"2006","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/16455309","citation_count":54,"is_preprint":false},{"pmid":"7720576","id":"PMC_7720576","title":"Genesis and prevention of spinal neural tube defects in the curly tail mutant mouse: involvement of retinoic acid and its nuclear receptors RAR-beta and RAR-gamma.","date":"1995","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/7720576","citation_count":50,"is_preprint":false},{"pmid":"30120411","id":"PMC_30120411","title":"The miR-96 and RARγ signaling axis governs androgen signaling and prostate cancer progression.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30120411","citation_count":48,"is_preprint":false},{"pmid":"15734736","id":"PMC_15734736","title":"Vinexin beta interacts with the non-phosphorylated AF-1 domain of retinoid receptor gamma (RARgamma) and represses RARgamma-mediated transcription.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15734736","citation_count":45,"is_preprint":false},{"pmid":"10523855","id":"PMC_10523855","title":"4HPR triggers apoptosis but not differentiation in retinoid sensitive and resistant human embryonal carcinoma cells through an RARgamma independent pathway.","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10523855","citation_count":44,"is_preprint":false},{"pmid":"28960887","id":"PMC_28960887","title":"Activation of RARα, RARγ, or RXRα Increases Barrier Tightness in Human Induced Pluripotent Stem Cell-Derived Brain Endothelial Cells.","date":"2017","source":"Biotechnology journal","url":"https://pubmed.ncbi.nlm.nih.gov/28960887","citation_count":40,"is_preprint":false},{"pmid":"12824162","id":"PMC_12824162","title":"The AF-1 and AF-2 domains of RAR gamma 2 and RXR alpha cooperate for triggering the transactivation and the degradation of RAR gamma 2/RXR alpha heterodimers.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12824162","citation_count":40,"is_preprint":false},{"pmid":"11784046","id":"PMC_11784046","title":"RARgamma and Cdx1 interactions in vertebral patterning.","date":"2001","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/11784046","citation_count":39,"is_preprint":false},{"pmid":"23097316","id":"PMC_23097316","title":"MIR-34c regulates mouse embryonic stem cells differentiation into male germ-like cells through RARg.","date":"2012","source":"Cell biochemistry and function","url":"https://pubmed.ncbi.nlm.nih.gov/23097316","citation_count":38,"is_preprint":false},{"pmid":"25510432","id":"PMC_25510432","title":"Critical role of retinoid/rexinoid signaling in mediating transformation and therapeutic response of NUP98-RARG leukemia.","date":"2014","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/25510432","citation_count":37,"is_preprint":false},{"pmid":"15094780","id":"PMC_15094780","title":"RARgamma acts as a tumor suppressor in mouse keratinocytes.","date":"2004","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15094780","citation_count":37,"is_preprint":false},{"pmid":"7631783","id":"PMC_7631783","title":"Marked resistance of RAR gamma-deficient mice to the toxic effects of retinoic acid.","date":"1995","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/7631783","citation_count":37,"is_preprint":false},{"pmid":"28871172","id":"PMC_28871172","title":"The cytoplasmic nuclear receptor RARγ controls RIP1 initiated cell death when cIAP activity is inhibited.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28871172","citation_count":36,"is_preprint":false},{"pmid":"12464434","id":"PMC_12464434","title":"The retinoic acid receptors RARalpha and RARgamma are required for inner ear development.","date":"2002","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/12464434","citation_count":35,"is_preprint":false},{"pmid":"32587261","id":"PMC_32587261","title":"Variation in RARG increases susceptibility to doxorubicin-induced cardiotoxicity in patient specific induced pluripotent stem cell-derived cardiomyocytes.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32587261","citation_count":34,"is_preprint":false},{"pmid":"24821986","id":"PMC_24821986","title":"Active repression by RARγ signaling is required for vertebrate axial elongation.","date":"2014","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/24821986","citation_count":34,"is_preprint":false},{"pmid":"22920668","id":"PMC_22920668","title":"Reversal by RARα agonist Am580 of c-Myc-induced imbalance in RARα/RARγ expression during MMTV-Myc tumorigenesis.","date":"2012","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/22920668","citation_count":34,"is_preprint":false},{"pmid":"8761883","id":"PMC_8761883","title":"Pattern of retinoid-induced teratogenic effects: possible relationship with relative selectivity for nuclear retinoid receptors RAR alpha, RAR beta, and RAR gamma.","date":"1996","source":"Teratology","url":"https://pubmed.ncbi.nlm.nih.gov/8761883","citation_count":34,"is_preprint":false},{"pmid":"10479291","id":"PMC_10479291","title":"Synthesis, structure-activity relationships, and RARgamma-ligand interactions of nitrogen heteroarotinoids.","date":"1999","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10479291","citation_count":33,"is_preprint":false},{"pmid":"8389582","id":"PMC_8389582","title":"The pattern of retinoic acid receptor gamma (RAR gamma) expression in normal development of Xenopus laevis and after manipulation of the main body axis.","date":"1993","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/8389582","citation_count":33,"is_preprint":false},{"pmid":"27756432","id":"PMC_27756432","title":"RARγ-induced E-cadherin downregulation promotes hepatocellular carcinoma invasion and metastasis.","date":"2016","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/27756432","citation_count":31,"is_preprint":false},{"pmid":"23518499","id":"PMC_23518499","title":"CDK1 interacts with RARγ and plays an important role in treatment response of acute myeloid leukemia.","date":"2013","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/23518499","citation_count":31,"is_preprint":false},{"pmid":"9376317","id":"PMC_9376317","title":"Limited specificity and large overlap of the functions of the mouse RAR gamma 1 and RAR gamma 2 isoforms.","date":"1997","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/9376317","citation_count":31,"is_preprint":false},{"pmid":"29891591","id":"PMC_29891591","title":"A case of acute myeloid leukemia with promyelocytic features characterized by expression of a novel RARG-CPSF6 fusion.","date":"2018","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/29891591","citation_count":30,"is_preprint":false},{"pmid":"8199051","id":"PMC_8199051","title":"Regional specificity of RAR gamma isoforms in Xenopus development.","date":"1994","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/8199051","citation_count":30,"is_preprint":false},{"pmid":"30996344","id":"PMC_30996344","title":"A novel NPM1-RARG-NPM1 chimeric fusion in acute myeloid leukaemia resembling acute promyelocytic leukaemia but resistant to all-trans retinoic acid and arsenic trioxide.","date":"2019","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30996344","citation_count":28,"is_preprint":false},{"pmid":"9116296","id":"PMC_9116296","title":"Downregulation of RAR alpha in mice by antisense transgene leads to a compensatory increase in RAR beta and RAR gamma and development of lymphoma.","date":"1997","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9116296","citation_count":28,"is_preprint":false},{"pmid":"20043900","id":"PMC_20043900","title":"Analysis of Cyp26b1/Rarg compound-null mice reveals two genetically separable effects of retinoic acid on limb outgrowth.","date":"2010","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/20043900","citation_count":26,"is_preprint":false},{"pmid":"19482478","id":"PMC_19482478","title":"Retinoid receptor subtype-selective modulators through synthetic modifications of RARgamma agonists.","date":"2009","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19482478","citation_count":26,"is_preprint":false},{"pmid":"25800721","id":"PMC_25800721","title":"RARγ is a negative regulator of osteoclastogenesis.","date":"2015","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25800721","citation_count":25,"is_preprint":false},{"pmid":"25173565","id":"PMC_25173565","title":"RARγ-C-Fos-PPARγ2 signaling rather than ROS generation is critical for all-trans retinoic acid-inhibited adipocyte differentiation.","date":"2014","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/25173565","citation_count":25,"is_preprint":false},{"pmid":"11212249","id":"PMC_11212249","title":"Increased retinoic acid responsiveness in lung carcinoma cells that are nonresponsive despite the presence of endogenous retinoic acid receptor (RAR) beta by expression of exogenous retinoid receptors retinoid X receptor alpha, RAR alpha, and RAR gamma.","date":"2001","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11212249","citation_count":25,"is_preprint":false},{"pmid":"36799929","id":"PMC_36799929","title":"A global study for acute myeloid leukemia with RARG rearrangement.","date":"2023","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/36799929","citation_count":23,"is_preprint":false},{"pmid":"19732752","id":"PMC_19732752","title":"Liganded RARalpha and RARgamma interact with but are repressed by TNIP1.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19732752","citation_count":23,"is_preprint":false},{"pmid":"29530751","id":"PMC_29530751","title":"RARA and RARG gene downregulation associated with EZH2 mutation in acute promyelocytic-like morphology leukemia.","date":"2018","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29530751","citation_count":22,"is_preprint":false},{"pmid":"20857416","id":"PMC_20857416","title":"RARγ is required for correct deposition and removal of Suz12 and H2A.Z in embryonic stem cells.","date":"2011","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/20857416","citation_count":22,"is_preprint":false},{"pmid":"33116634","id":"PMC_33116634","title":"Acute Myeloid Leukemia with NUP98-RARG Gene Fusion Similar to Acute Promyelocytic Leukemia: Case Report and Literature Review.","date":"2020","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33116634","citation_count":21,"is_preprint":false},{"pmid":"32017149","id":"PMC_32017149","title":"Clinical Pharmacology and Safety of Trifarotene, a First-in-Class RARγ-Selective Topical Retinoid.","date":"2020","source":"Journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32017149","citation_count":21,"is_preprint":false},{"pmid":"14648846","id":"PMC_14648846","title":"Function of RARgamma and RARalpha2 at the initiation of retinoid signaling is essential for avian embryo survival and for distinct events in cardiac morphogenesis.","date":"2003","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/14648846","citation_count":21,"is_preprint":false},{"pmid":"31709264","id":"PMC_31709264","title":"RARG Gene Dysregulation in Acute Myeloid Leukemia.","date":"2019","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/31709264","citation_count":20,"is_preprint":false},{"pmid":"34411225","id":"PMC_34411225","title":"RARγ activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway.","date":"2022","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/34411225","citation_count":19,"is_preprint":false},{"pmid":"27261179","id":"PMC_27261179","title":"Identification of potent and selective retinoic acid receptor gamma (RARγ) antagonists for the treatment of osteoarthritis pain using structure based drug design.","date":"2016","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/27261179","citation_count":19,"is_preprint":false},{"pmid":"33807298","id":"PMC_33807298","title":"The RARγ Oncogene: An Achilles Heel for Some Cancers.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33807298","citation_count":18,"is_preprint":false},{"pmid":"35364012","id":"PMC_35364012","title":"RARG S427L attenuates the DNA repair response to doxorubicin in induced pluripotent stem cell-derived cardiomyocytes.","date":"2022","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/35364012","citation_count":18,"is_preprint":false},{"pmid":"24459144","id":"PMC_24459144","title":"Retinoic acid receptor γ (Rarg) and nuclear receptor subfamily 5, group A, member 2 (Nr5a2) promote conversion of fibroblasts to functional neurons.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24459144","citation_count":18,"is_preprint":false},{"pmid":"29848550","id":"PMC_29848550","title":"Combinatorial knockout of RARα, RARβ, and RARγ completely abrogates transcriptional responses to retinoic acid in murine embryonic stem cells.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29848550","citation_count":18,"is_preprint":false},{"pmid":"33019444","id":"PMC_33019444","title":"Alkaloid-based regimen is beneficial for acute myeloid leukemia resembling acute promyelocytic leukemia with NUP98/RARG fusion and RUNX1 mutation: A case report.","date":"2020","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33019444","citation_count":18,"is_preprint":false},{"pmid":"36175396","id":"PMC_36175396","title":"Retinoic acid and RARγ maintain satellite cell quiescence through regulation of translation initiation.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36175396","citation_count":17,"is_preprint":false},{"pmid":"26531761","id":"PMC_26531761","title":"TSLP expression in the skin is mediated via RARγ-RXR pathways.","date":"2015","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/26531761","citation_count":16,"is_preprint":false},{"pmid":"11141350","id":"PMC_11141350","title":"Synergistic teratogenic effects induced by retinoids in mice by coadministration of a RARalpha- or RARgamma-selective agonist with a RXR-selective agonist.","date":"2001","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11141350","citation_count":16,"is_preprint":false},{"pmid":"18715802","id":"PMC_18715802","title":"Regulation of CD8(+) T cell functions by RARgamma.","date":"2008","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18715802","citation_count":14,"is_preprint":false},{"pmid":"36031407","id":"PMC_36031407","title":"Synthetic Retinoid Kills Drug-Resistant Cancer Stem Cells via Inducing RARγ-Translocation-Mediated Tension Reduction and Chromatin Decondensation.","date":"2022","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/36031407","citation_count":14,"is_preprint":false},{"pmid":"33252195","id":"PMC_33252195","title":"Temporal activation of LRH-1 and RAR-γ in human pluripotent stem cells induces a functional naïve-like state.","date":"2020","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/33252195","citation_count":14,"is_preprint":false},{"pmid":"33473264","id":"PMC_33473264","title":"Acute myeloid leukemia with CPSF6-RARG fusion resembling acute promyelocytic leukemia with extramedullary infiltration.","date":"2021","source":"Therapeutic advances in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/33473264","citation_count":14,"is_preprint":false},{"pmid":"10672865","id":"PMC_10672865","title":"RAR gamma agonists inhibit proliferation of vascular smooth muscle cells.","date":"2000","source":"Journal of cardiovascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10672865","citation_count":14,"is_preprint":false},{"pmid":"36523991","id":"PMC_36523991","title":"High expression of RARG accelerates ovarian cancer progression by regulating cell proliferation.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36523991","citation_count":13,"is_preprint":false},{"pmid":"35731978","id":"PMC_35731978","title":"A non-retinol retinoic acid receptor-γ (RAR-γ/NR1B3) selective agonist, tectorigenin, can effectively inhibit the ultraviolet A-induced skin damage.","date":"2022","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35731978","citation_count":13,"is_preprint":false},{"pmid":"10374844","id":"PMC_10374844","title":"The RARgamma selective agonist CD437 inhibits gastric cell growth through the mechanism of apoptosis.","date":"1999","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/10374844","citation_count":13,"is_preprint":false},{"pmid":"9016769","id":"PMC_9016769","title":"Purification of the human RARgamma ligand-binding domain and crystallization of its complex with all-trans retinoic acid.","date":"1997","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9016769","citation_count":13,"is_preprint":false},{"pmid":"16280299","id":"PMC_16280299","title":"Comedolytic effect of a novel RARgamma-specific retinoid, ER36009: comparison with retinoic acid in the rhino mouse model.","date":"2005","source":"European journal of dermatology : EJD","url":"https://pubmed.ncbi.nlm.nih.gov/16280299","citation_count":13,"is_preprint":false},{"pmid":"39046762","id":"PMC_39046762","title":"Critical role of tripartite fusion and LBD truncation in certain RARA- and all RARG-related atypical APL.","date":"2024","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/39046762","citation_count":12,"is_preprint":false},{"pmid":"36331922","id":"PMC_36331922","title":"All-trans retinoic acid (ATRA) regulates key genes in the RARG-TOP2B pathway and reduces anthracycline-induced cardiotoxicity.","date":"2022","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/36331922","citation_count":12,"is_preprint":false},{"pmid":"35544458","id":"PMC_35544458","title":"A short report of novel RARG-HNRNPM fusion gene in resembling acute promyelocytic leukemia.","date":"2022","source":"Hematology (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/35544458","citation_count":12,"is_preprint":false},{"pmid":"32294904","id":"PMC_32294904","title":"Understanding the Action of RARγ Agonists on Human Osteochondroma Explants.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32294904","citation_count":12,"is_preprint":false},{"pmid":"37198667","id":"PMC_37198667","title":"Blockage of retinoic acid signaling via RARγ suppressed the proliferation of pancreatic cancer cells by arresting the cell cycle progression of the G1-S phase.","date":"2023","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/37198667","citation_count":12,"is_preprint":false},{"pmid":"36713535","id":"PMC_36713535","title":"Case report: Identification of a novel HNRNPC::RARG fusion in acute promyelocytic leukemia lacking RARA rearrangement.","date":"2023","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36713535","citation_count":12,"is_preprint":false},{"pmid":"31694553","id":"PMC_31694553","title":"Postoperative cognitive dysfunction after robot-assisted radical cystectomy (RARC) with cerebral oxygen monitoring an observational prospective cohort pilot study.","date":"2019","source":"BMC anesthesiology","url":"https://pubmed.ncbi.nlm.nih.gov/31694553","citation_count":12,"is_preprint":false},{"pmid":"1337576","id":"PMC_1337576","title":"Retinoic acid receptor isoform RAR gamma 1: an antagonist of the transactivation of the RAR beta RARE in epithelial cell lines and normal human keratinocytes.","date":"1992","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/1337576","citation_count":12,"is_preprint":false},{"pmid":"32245464","id":"PMC_32245464","title":"Surgical management of bilateral hip fractures in a patient with fibrodysplasia ossificans progressiva treated with the RAR-γ agonist palovarotene: a case report.","date":"2020","source":"BMC musculoskeletal disorders","url":"https://pubmed.ncbi.nlm.nih.gov/32245464","citation_count":11,"is_preprint":false},{"pmid":"35563205","id":"PMC_35563205","title":"Antagonizing RARγ Drives Necroptosis of Cancer Stem Cells.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35563205","citation_count":10,"is_preprint":false},{"pmid":"10559481","id":"PMC_10559481","title":"Hoxd4 and Rarg interact synergistically in the specification of the cervical vertebrae.","date":"1999","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/10559481","citation_count":10,"is_preprint":false},{"pmid":"10910773","id":"PMC_10910773","title":"The conserved amphipatic alpha-helical core motif of RARgamma and RARalpha activating domains is indispensable for RA-induced differentiation of F9 cells.","date":"2000","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/10910773","citation_count":10,"is_preprint":false},{"pmid":"28933645","id":"PMC_28933645","title":"RARα and RARγ reciprocally control K5+ progenitor cell expansion in developing salivary glands.","date":"2017","source":"Organogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/28933645","citation_count":9,"is_preprint":false},{"pmid":"25088254","id":"PMC_25088254","title":"BCL-xL/MCL-1 inhibition and RARγ antagonism work cooperatively in human HL60 leukemia cells.","date":"2014","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/25088254","citation_count":9,"is_preprint":false},{"pmid":"15790515","id":"PMC_15790515","title":"Ligation of RARgamma inhibits proliferation of phytohaemagglutinin-stimulated T-cells via down-regulating JAK3 protein levels.","date":"2004","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/15790515","citation_count":9,"is_preprint":false},{"pmid":"37897947","id":"PMC_37897947","title":"RARγ promotes the invasion and metastasis of thyroid carcinoma by activating the JAK1-STAT3-CD24/MMPs axis.","date":"2023","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37897947","citation_count":8,"is_preprint":false},{"pmid":"35319505","id":"PMC_35319505","title":"A Novel NUP98/RARG Gene Fusion in Pediatric Acute Myeloid Leukemia Resembling Acute Promyelocytic Leukemia.","date":"2022","source":"Journal of pediatric hematology/oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35319505","citation_count":8,"is_preprint":false},{"pmid":"14991612","id":"PMC_14991612","title":"Retinoids induce Fas(CD95) ligand cell surface expression via RARgamma and nur77 in T cells.","date":"2004","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14991612","citation_count":8,"is_preprint":false},{"pmid":"17185799","id":"PMC_17185799","title":"Topical ER36009, a RARgamma-selective retinoid, decreases abdominal white adipose tissue and elicits changes in expression of genes related to adiposity and thermogenesis.","date":"2006","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/17185799","citation_count":8,"is_preprint":false},{"pmid":"39805831","id":"PMC_39805831","title":"Oncogenic role of RARG rearrangements in acute myeloid leukemia resembling acute promyelocytic leukemia.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39805831","citation_count":7,"is_preprint":false},{"pmid":"39805830","id":"PMC_39805830","title":"CPSF6-RARγ interacts with histone deacetylase 3 to promote myeloid transformation in RARG-fusion acute myeloid leukemia.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39805830","citation_count":7,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48357,"output_tokens":9708,"usd":0.145345,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20405,"output_tokens":5063,"usd":0.1143,"stage2_stop_reason":"end_turn"},"total_usd":0.259645,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"Crystal structure of the RARγ ligand-binding domain (LBD) bound to all-trans retinoic acid at 2.0 Å resolution reveals ligand-binding interactions and a 'mouse trap' mechanism: ligand binding induces a conformational transition that repositions the C-terminal amphipathic alpha-helix (AF-2 activating domain) to form a transcriptionally active receptor, sealing the ligand pocket.\",\n      \"method\": \"X-ray crystallography (2.0 Å resolution crystal structure)\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — atomic-resolution crystal structure with mechanistic interpretation, foundational study widely replicated\",\n      \"pmids\": [\"7501014\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Purification of human RARγ LBD (residues 178–423) and determination that its Kd for all-trans retinoic acid is 0.6 ± 0.1 nM; crystals of the LBD–ligand complex were grown and confirmed to diffract to 2.0 Å.\",\n      \"method\": \"Recombinant protein purification (E. coli), ligand-binding assay, X-ray crystallography\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with quantitative binding measurement and structural validation\",\n      \"pmids\": [\"9016769\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"1.4 Å crystal structure of RARγ LBD complexed with retinoid SR11254 reveals multiple C-H…O hydrogen bonds between the ligand hydroxyl and the hydrophobic ligand pocket, providing a structural basis for receptor-subtype selectivity and affinity.\",\n      \"method\": \"X-ray crystallography (1.4 Å resolution)\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — high-resolution crystal structure with direct structural analysis of ligand interactions\",\n      \"pmids\": [\"12220491\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"RARγ2 expression is autoregulated through a retinoic acid response element (RARE) in its own promoter, consisting of a 6-bp direct repeat with a 5-nucleotide spacer; this RARE is bound most effectively by RAR/RXR heterodimers, and Sp1 binding sites flanking the RARE synergistically enhance RARγ2 promoter activity.\",\n      \"method\": \"Reporter gene assays, cotransfection, mutational analysis of RARE, EMSA (receptor binding to RARE)\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (reporter assays, mutagenesis, binding assays) in a single rigorous study\",\n      \"pmids\": [\"1320193\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Targeted disruption of RARγ in F9 embryonal carcinoma cells specifically impairs RA-induced expression of Hoxa-1, Hoxa-3, laminin B1, collagen IV (α1), GATA-4, and BMP-2, and reduces metabolism of all-trans-RA to polar derivatives, demonstrating that RARγ regulates a distinct subset of RA target genes and RA metabolism.\",\n      \"method\": \"Homologous recombination knockout, RT-PCR/Northern blot for target gene expression, RA metabolism assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean knockout with multiple target gene readouts and metabolic assay, replicated across labs\",\n      \"pmids\": [\"7823950\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"RAR-RXR heterodimers require activation of both partners for synergistic induction of RA-responsive endogenous genes and differentiation of P19 and F9 cells; RARγ-selective retinoids combined with RXR-selective retinoids synergistically induce differentiation, demonstrating functional redundancy between RARα, RARβ, and RARγ in this context.\",\n      \"method\": \"Selective synthetic retinoids in cell-based differentiation assays, gene expression analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — systematic pharmacological dissection with isoform-selective ligands across multiple endpoints and cell lines\",\n      \"pmids\": [\"8524212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Reexpression of RARγ2 in RARγ-null F9 cells restores both RA-target gene activation (Cdx1, Gap43, Stra4, Stra6) and differentiation potential; overexpression of RARα can partially substitute, but RARβ overexpression only poorly restores differentiation, establishing partial functional redundancy between RAR subtypes with RARγ as the primary mediator of differentiation.\",\n      \"method\": \"Stable rescue cell lines, RT-PCR for target gene expression, morphological differentiation assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic rescue with isoform-specific re-expression, multiple orthogonal readouts, complementary to knockout study\",\n      \"pmids\": [\"7644503\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Phosphorylation of both AF-1 and AF-2 activation functions of RARγ2 is required for RA-induced primitive endodermal differentiation of F9 cells; AF-1 phosphorylation at the proline-directed kinase site of RARγ2 is specifically required for primitive endoderm, while parietal differentiation additionally requires RARα1 AF-1 phosphorylation and PKA-site phosphorylation of RARα AF-2.\",\n      \"method\": \"Phosphorylation site mutagenesis, stable cell lines in RARγ-null F9 cells, differentiation assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis of specific phosphorylation sites with functional rescue, multiple isoforms tested\",\n      \"pmids\": [\"9351827\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Upon RA binding, RARγ2 undergoes proteasome-dependent degradation signaled through both AF-1 (phosphorylated by p38MAPK) and AF-2 (via recruitment of SUG-1, a component of the 19S regulatory subunit of the 26S proteasome); blocking either p38MAPK or proteasome function impairs RARγ2 transactivation activity, linking receptor turnover to transcriptional activation.\",\n      \"method\": \"Pharmacological inhibition of p38MAPK and proteasome, co-immunoprecipitation of SUG-1, mutagenesis of AF-1/AF-2, reporter gene assays, pulse-chase degradation assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (Co-IP, mutagenesis, kinase inhibition, reporter assays, protein stability assay) in single rigorous study\",\n      \"pmids\": [\"12110588\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"RARγ2 is the 'engine' of the RAR heterodimer driving both transcription and its own proteasomal degradation after ligand binding; integrity of its AF-2 domain and phosphorylation of its AF-1 domain are required for both degradation and transactivation; RXRα plays a modulatory/cooperative role through its own AF-1 (phosphorylated) and AF-2 domains.\",\n      \"method\": \"Domain deletion mutants, AF-1 phosphorylation site mutants, transfection assays, ubiquitin-proteasome pathway analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — systematic mutagenesis of both heterodimer partners with multiple functional readouts\",\n      \"pmids\": [\"12824162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Vinexin β, a SH3 motif-containing cytoskeletal protein, interacts with the non-phosphorylated AF-1 domain of RARγ (but not RARα or RARβ); upon phosphorylation of AF-1, vinexin β dissociates. Vinexin β colocalizes with RARγ in the nucleus and functions as a repressor of RARγ-mediated transcription, as demonstrated by overexpression and RNAi knockdown.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, immunofluorescence colocalization, stable overexpression, siRNA knockdown, reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal protein interaction confirmed by yeast two-hybrid and Co-IP, localization data, and functional assays with both gain- and loss-of-function\",\n      \"pmids\": [\"15734736\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"A nonsynonymous coding variant in RARG (rs2229774, p.Ser427Leu) is associated with anthracycline-induced cardiotoxicity; this variant alters RARG function, leading to derepression of TOP2B (topoisomerase 2β), which is a key genetic determinant of anthracycline-induced cardiotoxicity.\",\n      \"method\": \"GWAS with functional validation: reporter/expression assays showing derepression of TOP2B by RARG S427L variant\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — GWAS discovery with functional validation, replicated in three independent cohorts, mechanistic pathway identified\",\n      \"pmids\": [\"26237429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The RARG S427L variant (rs2229774) mediates increased doxorubicin-induced cardiotoxicity by suppressing TOP2B expression and failing to activate the cardioprotective ERK pathway; the RARγ agonist CD1530 attenuates doxorubicin-induced cardiotoxicity in patient-specific hiPSC-CMs and in vivo mouse models.\",\n      \"method\": \"Patient-specific hiPSC-CMs, CRISPR isogenic lines, molecular pathway analysis (ERK, TOP2B), in vivo mouse DIC model, pharmacological rescue\",\n      \"journal\": \"Cell stem cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — isogenic CRISPR lines with mechanistic pathway dissection validated in vivo, multiple orthogonal methods\",\n      \"pmids\": [\"34525346\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CRISPR/Cas9 correction of RARG-S427L to wild type reduces doxorubicin-induced double-stranded DNA breaks, ROS production, and cell death in iPSC-CMs; introduction of S427L increases susceptibility; genetic disruption of RARG protects from doxorubicin-induced cell death, establishing a direct causal role for RARG S427L in DIC.\",\n      \"method\": \"CRISPR/Cas9 isogenic iPSC-CM lines, cell viability, optical mapping, DNA damage (γH2AX), ROS assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — isogenic CRISPR knockin/correction with multiple cellular readouts, bidirectional genetic manipulation\",\n      \"pmids\": [\"32587261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"RARG p.S427L variant leads to reduced activation of RARG target genes (including DNA repair pathways) in response to doxorubicin in iPSC-CMs, resulting in impaired DNA repair; molecular dynamic simulations predict structural changes confirmed by gene expression studies.\",\n      \"method\": \"Molecular dynamic simulations, CRISPR-edited iPSC-CMs, RNA-Seq, DNA damage assays\",\n      \"journal\": \"Stem cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR isogenic lines with RNA-Seq, structural prediction validated functionally; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"35364012\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ATRA activates RARγ, induces interferon-β response and IRF1 expression; IRF1 initiates transcription of OAS1, which synthesizes 2-5A to activate RNase L and cause RNA degradation and cell death, thereby sensitizing multiple myeloma cells to carfilzomib; selective RARγ agonist BMS961 recapitulates this effect.\",\n      \"method\": \"High-throughput drug screen, selective RARγ agonist, gene knockdown, reporter assays, in vivo myeloma model\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and genetic dissection of pathway in vitro and in vivo, but full mechanistic reconstitution not reported; single lab\",\n      \"pmids\": [\"34411225\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"RARγ is selectively expressed in primitive hematopoietic precursors; RARγ knockout mice show markedly reduced HSC numbers with increased mature progenitors; overexpression of RARγ (but not RARα) in primitive precursors maintains an undifferentiated phenotype; pharmacological RARγ activation promotes HSC self-renewal as shown by serial transplant studies.\",\n      \"method\": \"RARγ knockout mice, competitive transplantation, retroviral overexpression, ex vivo culture with selective agonists, serial transplant\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function, gain-of-function, and pharmacological approaches with quantitative cellular readouts and serial transplant validation\",\n      \"pmids\": [\"16682494\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"In embryonic stem cells, RARγ (in the absence of ligand RA) is required for deposition of the histone variant H2A.Z and polycomb group protein Suz12 at RA target gene loci; RARγ and Suz12 exist in a multi-protein complex in the absence of ligand. Upon RA addition, H2A.Z and Suz12 are removed from these loci concurrent with transcriptional activation.\",\n      \"method\": \"ChIP, co-immunoprecipitation, RARγ-null ES cells\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and ChIP in null ES cells; single lab, two orthogonal methods\",\n      \"pmids\": [\"20857416\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"RARγ is required for RA-induced chromatin remodeling (H3K9/K14ac increase at proximal promoters) and transcriptional activation of a subset of RA target genes (e.g., Meis1, Lrat, Stra6, Crabp2, Cyp26a1) in embryonic stem cells; H3K4me3 at Meis1 proximal promoter does not require RARγ, revealing gene-specific epigenetic requirements.\",\n      \"method\": \"RARγ knockout ES cells, RNA-Seq/RT-PCR, ChIP for H3K9/K14ac and H3K4me3\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic null cells with genome-wide transcriptome and locus-specific ChIP, multiple chromatin marks analyzed\",\n      \"pmids\": [\"23264745\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"In Cyp26a1-null mice, ectopic RA signaling in the tail bud is mediated specifically by RARγ; activated RARγ downregulates Wnt3a and Fgf8. Genetic ablation of Rarg rescues Cyp26a1-null mice from caudal regression and embryonic lethality, demonstrating that CYP26A1 suppresses RARγ-mediated downregulation of WNT3A and FGF8 signaling pathways.\",\n      \"method\": \"Compound Cyp26a1/Rarg double knockout mice, in situ hybridization for Wnt3a and Fgf8, embryo survival analysis\",\n      \"journal\": \"Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with double knockout rescue and downstream pathway gene expression analysis\",\n      \"pmids\": [\"12588859\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"TNIP1 acts as an atypical corepressor of agonist-bound RARα and RARγ: it requires NR boxes, ligand, and the receptor's AF-2 domain for interaction (properties characteristic of coactivators), yet represses RAR activity; repression is partially relieved by SRC1; preferential interaction of RARα over RARγ maps to helices 5–9 of the RARα LBD.\",\n      \"method\": \"Co-immunoprecipitation, deletion/domain mutants, reporter gene assays, competitive binding with SRC1\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP with domain mapping and functional reporter assays, single lab\",\n      \"pmids\": [\"19732752\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Cytoplasmic RARγ controls RIP1-initiated apoptosis and necroptosis when cIAP activity is blocked downstream of TNF receptor 1; RARγ mediates RIP1 dissociation from TNFR1, initiating cytosolic death complex (complex II/necrosome) formation. In response to cIAP inhibition, RARγ is released from the nucleus to orchestrate formation of cytosolic death complexes.\",\n      \"method\": \"shRNA library screen, RARγ knockdown/knockout, co-immunoprecipitation of TNFR1-RIP1 complex, subcellular fractionation, in vivo TNF-induced necroptosis model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic screen validation, Co-IP of signaling complex, subcellular localization, in vivo confirmation\",\n      \"pmids\": [\"28871172\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"RARγ2 is engaged in active transcriptional repression (via co-repressor complex) throughout axial elongation in Xenopus, not only as a terminator; in the absence of RA, unliganded RARγ2 represses caudal progenitor genes to maintain the progenitor pool; upon RA, RARγ2 switches to activator, facilitating somite differentiation. Dominant-negative co-repressor or VP16-RARγ2 overexpression prematurely terminates axis elongation.\",\n      \"method\": \"Dominant-negative RARγ overexpression, selective RARγ inverse agonist (NRX205099) and agonist (NRX204647), dominant-negative co-repressor (c-SMRT), Xenopus embryo in vivo assays, in situ hybridization\",\n      \"journal\": \"Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic and pharmacological tools with in vivo readouts in Xenopus\",\n      \"pmids\": [\"24821986\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"NUP98-RARG fusion protein acquires nuclear localization patterns and transcriptional properties similar to RARA fusions; its oncogenic transformation of hematopoietic stem/progenitor cells depends on the C-terminal GLFG domain of NUP98 and the DNA-binding domain of RARG; NUP98-RARG homodimerizes and recruits both RXRA and wild-type NUP98; transformed cells are sensitive to ATRA.\",\n      \"method\": \"Murine bone marrow retroviral transduction/transformation assay, domain deletion mutants, nuclear localization imaging, reporter gene assays, Co-IP\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — systematic mutagenesis in transformation assay, Co-IP of protein complex, multiple orthogonal functional readouts\",\n      \"pmids\": [\"25510432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"RARγ promotes phosphorylation of Lats1 and Yap binding to Lats1, thereby inactivating Yap target gene expression and suppressing colorectal cancer; knockdown of RARγ activates Hippo-Yap oncogenic signaling, driving cancer cell growth, invasion, and metastasis.\",\n      \"method\": \"RARγ knockdown, Co-IP of Lats1-Yap, phosphorylation assays, in vitro invasion assays, in vivo xenograft\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP/phosphorylation data with in vitro and in vivo functional readouts; single lab\",\n      \"pmids\": [\"27325643\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In macrophages, RARγ interacts with TRAF6 and prevents TRAF6 oligomerization and autoubiquitination, thereby inhibiting NF-κB signaling; tumor-derived lactate drives H3K18 lactylation to suppress RARγ gene transcription, releasing TRAF6 to promote IL-6/STAT3 signaling. NDGA directly binds RARγ to inhibit TRAF6-IL-6-STAT3 axis.\",\n      \"method\": \"Co-immunoprecipitation of RARγ-TRAF6, chromatin modification analysis (H3K18 lactylation ChIP), TRAF6 ubiquitination assays, direct binding assay (NDGA-RARγ), in vivo colorectal cancer models\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, ubiquitination assay, chromatin modification ChIP, and direct ligand binding with in vivo validation\",\n      \"pmids\": [\"38245869\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CPSF6-RARG fusion (CR) interacts with HDAC3 to suppress expression of myeloid differentiation genes including PU.1; disrupting the CR-HDAC3 interaction restores PU.1 expression and myeloid differentiation; HDAC inhibitors suppress CR-driven leukemia in vitro and in vivo.\",\n      \"method\": \"Co-immunoprecipitation of CR-HDAC3, gene expression analysis, HDAC inhibitor treatment, in vivo leukemia model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP establishing physical complex, functional rescue by disruption of interaction, in vivo validation\",\n      \"pmids\": [\"39805830\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"RARG fusions disrupt myeloid differentiation and promote HSPC proliferation/self-renewal by upregulating BCL2 and ATF3; co-occurrence with heterozygous Wt1 loss induces fully penetrant AML by activating MYC and HOXA9/MEIS1 targets; all RARG-aAPL cases harbor tripartite X::RARG::X fusions with truncation of LBD helix 11–12, which is mechanistically responsible for ATRA unresponsiveness through protein allosteric dysfunction.\",\n      \"method\": \"Retroviral transduction/transformation assays, RNA-Seq, molecular structure analysis, high-throughput drug screening (Connectivity Map)\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo leukemia model, transcriptomic pathway dissection, structural analysis, genetic epistasis (Wt1 loss), validated in 21 RARG-aAPL cases\",\n      \"pmids\": [\"39805831\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"All RARG-aAPL cases harbor tripartite X::RARG::Y fusion transcripts with RARG 3' splice consistently at the terminus of exon 9, resulting in LBD helix 11–12 truncation; this truncation (not present in artificially mimicked bipartite fusions) drives ATRA unresponsiveness and leukemogenesis through protein allosteric dysfunction.\",\n      \"method\": \"Molecular investigation of fusion transcripts in 21 RARG-aAPL cases, protein structural analysis, experimental functional assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — systematic molecular characterization with structural analysis and experimental validation across 21 patient cases\",\n      \"pmids\": [\"39046762\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CDK1 interacts with RARγ in the nucleus; RARγ regulates CDK1 protein levels and its subcellular localization in response to ATRA; CDK1 is required for optimal ATRA effect in U-937 leukemic cells and modulates P27(kip) and AKT phosphorylation; CDK1 and RARγ form a reciprocal regulatory circuit influencing each other's protein stability.\",\n      \"method\": \"Co-immunoprecipitation, subcellular fractionation, CDK1 inhibition, immunofluorescence, Western blot in leukemia cells\",\n      \"journal\": \"Cell cycle\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP with functional correlates, single lab\",\n      \"pmids\": [\"23518499\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"In ATRA-inhibited adipocyte differentiation, RARγ (but not RARα) interacts with C-Fos protein; this interaction inhibits C-Fos DNA binding activity at the PPARγ2 promoter, reducing PPARγ2 expression and blocking adipocyte differentiation; RARγ inhibitor blocks ATRA-induced reduction of C-Fos binding to PPARγ2 promoter.\",\n      \"method\": \"Co-immunoprecipitation of RARγ-C-Fos, chromatin immunoprecipitation (ChIP) for C-Fos at PPARγ2 promoter, RARγ inhibitor, Western blot\",\n      \"journal\": \"Biochimie\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and ChIP with pharmacological inhibitor validation, single lab\",\n      \"pmids\": [\"25173565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"RARγ binds to and stimulates genes responsible for Akt dephosphorylation in satellite cells, inhibiting overall protein translation initiation to maintain quiescence; alleviation of retinoic acid signaling releases satellite cells from quiescence; this restraint is lost in aged cells.\",\n      \"method\": \"ChIP for RARγ occupancy at target genes, in vivo satellite cell activation assays, RA signaling inhibition, aged vs. young muscle comparison\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP with functional in vivo readouts; single lab, mechanistic pathway partially established\",\n      \"pmids\": [\"36175396\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"miR-96 directly targets RARγ mRNA to downregulate RARγ expression; reduced RARγ levels (independent of exogenous retinoid) impact prostate cell viability; RARγ cistrome is enriched at active enhancers associated with AR binding sites, and RARγ knockdown significantly alters the magnitude of the AR transcriptome.\",\n      \"method\": \"miR-96 mimic/biotin-miR-96 targetome capture, luciferase 3'UTR reporter assay, ChIP-Seq (RARγ cistrome), shRNA knockdown, RNA-Seq\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct targetome capture and luciferase validation, ChIP-Seq cistrome; single lab\",\n      \"pmids\": [\"30120411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A synthetic retinoid induces RARγ translocation from the nucleus to the cytoplasm; nuclear RARγ normally binds the Cdc42 promoter; cytoplasmic translocation reduces RARγ-Cdc42 promoter binding, downregulating Cdc42, decreasing F-actin, and inhibiting cytoskeletal tension, leading to chromatin decondensation and DNA damage in tumor-repopulating cells.\",\n      \"method\": \"Immunofluorescence/live imaging for RARγ translocation, ChIP for RARγ at Cdc42 promoter, Cdc42/F-actin rescue experiments, tumor-repopulating cell apoptosis assay\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and imaging with rescue experiments; single lab, mechanistic chain partially validated\",\n      \"pmids\": [\"36031407\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Ligation of RARγ (but not RARα) by selective agonists inhibits proliferation of PHA-stimulated T cells by preventing IL-2-induced upregulation of JAK3 protein levels (without affecting JAK1), thereby inhibiting STAT5 phosphorylation and Rb phosphorylation.\",\n      \"method\": \"Selective RARγ agonists, RARγ antagonist, Western blot for JAK1/JAK3/STAT5/Rb, T cell proliferation assay\",\n      \"journal\": \"Immunology letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — pharmacological approach with isoform-selective compounds, multiple signaling readouts; single lab\",\n      \"pmids\": [\"15790515\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"In IP-12-7 T cells, RA induces nur77 expression and DNA binding, and FasL cell surface appearance via RARγ; two RARγ-selective compounds (CD437 and CD2325) initiate apoptosis while natural RA cannot, because natural RA-liganded RARγ cannot sensitize the Fas death pathway even though it induces FasL expression.\",\n      \"method\": \"Selective RAR agonists/antagonists, EMSA for nur77 DNA binding, flow cytometry for FasL surface expression, apoptosis assays\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — pharmacological approach with receptor-selective ligands and multiple readouts; single lab\",\n      \"pmids\": [\"14991612\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"RARγ and Cdx1 interact synergistically in vertebral patterning: compound RARγ-Cdx1 double null mutants show increased severity of cervical homeotic transformations relative to single nulls; exogenous RA requires Cdx1 for full vertebral morphogenetic effects, placing RARγ upstream of Cdx1 in axial patterning while also indicating parallel pathways converging on common targets.\",\n      \"method\": \"Compound null mouse genetics, skeletal phenotype analysis, RA treatment of compound nulls\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — complete allelic series with genetic epistasis analysis, RA treatment of multiple genotypes\",\n      \"pmids\": [\"11784046\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The conserved amphipathic alpha-helical core motif (helix 12) of RARγ AF-2 is required for RA-induced differentiation of F9 cells and RA target gene expression; AF-2 deletion mutants of RARγ2 and RARα1 behave as dominant negatives, blocking differentiation.\",\n      \"method\": \"Stable cell lines expressing AF-2 deletion mutants in RARγ-null F9 cells, differentiation assays, target gene expression analysis\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — structure-function mutagenesis with clear dominant-negative phenotype; single lab but mechanistically definitive\",\n      \"pmids\": [\"10910773\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Combinatorial knockout of all three RAR isoforms (RARα, RARβ, RARγ) by CRISPR completely abrogates all transcriptional responses to RA in murine embryonic stem cells, demonstrating that the transcriptional effects of RA are entirely RAR-dependent with no RAR-independent transcriptional route.\",\n      \"method\": \"CRISPR biallelic knockout of all three RARs, RNA-Seq transcriptome analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — complete genetic ablation of all three RARs with genome-wide transcriptome readout; definitive result\",\n      \"pmids\": [\"29848550\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"RARγ is a ligand-activated nuclear receptor that, upon all-trans retinoic acid binding, undergoes a 'mouse trap' conformational change repositioning the AF-2/helix-12 to form an active transcriptional complex; its AF-1 domain is phosphorylated by p38MAPK, enabling dissociation of the corepressor vinexin β and recruitment of SUG-1 (19S proteasome subunit) to drive coupled transcriptional activation and proteasomal degradation; as a heterodimer with RXRα, it binds RAREs to regulate a distinct subset of RA target genes (including Hoxa-1, Cdx1, Meis1, Stra6, TOP2B) via epigenetic mechanisms (H2A.Z/Suz12 deposition in ground state; H3K9/K14ac induction upon activation); it also operates as a cytoplasmic signaling scaffold (released from nucleus to mediate RIP1-initiated TNF death complex formation) and interacts with partners including TRAF6 (inhibiting NF-κB), CDK1, C-Fos, and HDAC3 (in RARG fusion leukemia); a coding variant (S427L) reduces RARγ activity, derepresses TOP2B, and increases anthracycline cardiotoxicity; RARG fusion proteins in AML acquire LBD helix 11–12 truncations that render them ATRA-unresponsive and leukemogenic through allosteric dysfunction and HDAC3 recruitment.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"RARγ is a ligand-activated nuclear receptor that, as a heterodimer with RXRα bound to retinoic acid response elements, transduces all-trans retinoic acid (RA) signals into transcriptional programs governing cellular differentiation, axial patterning, and stem cell fate [#3, #5, #38]. Atomic-resolution structures of its ligand-binding domain established the 'mouse trap' mechanism, in which RA binding repositions the C-terminal AF-2 helix-12 to seal the ligand pocket and create a transcriptionally active surface [#0, #1]; integrity of this AF-2 helix is obligatory for RA-induced differentiation, and AF-2 deletions act as dominant negatives [#37]. Productive transactivation additionally requires p38MAPK phosphorylation of the AF-1 domain, which both releases the corepressor vinexin β and couples receptor turnover to activation through recruitment of the 19S proteasome subunit SUG-1 [#8, #9, #10]. RARγ controls a distinct subset of RA target genes (Hoxa-1, Cdx1, Stra6, Meis1, Cyp26a1) and the differentiation of embryonal carcinoma and embryonic stem cells, acting through epigenetic switching: in the unliganded state it nucleates an H2A.Z/Suz12 repressive configuration that is replaced by H3K9/K14 acetylation upon ligand-driven activation [#4, #6, #17, #18]. In vivo it is the dominant RAR mediator of caudal axial patterning, restraining Wnt3a and Fgf8 to terminate axis elongation, and it maintains hematopoietic stem cell self-renewal and satellite-cell quiescence [#19, #22, #16, #31]. Beyond the nucleus, RARγ functions as a cytoplasmic signaling scaffold: it is released from the nucleus to drive RIP1-dependent TNFR1 death-complex assembly, and it restrains inflammatory signaling by binding TRAF6 to block its oligomerization and NF-κB activation [#21, #25]. A coding variant (p.Ser427Leu) reduces RARγ activity and derepresses TOP2B, impairing DNA repair and the cardioprotective ERK response to confer anthracycline-induced cardiotoxicity, which is reversed by genetic correction or RARγ agonists [#11, #12, #13, #14]. RARG fusion proteins (NUP98-, CPSF6-, and tripartite X::RARG::Y) cause an atypical acute promyelocytic leukemia: consistent truncation of LBD helix 11-12 renders them ATRA-unresponsive, and they recruit HDAC3 to suppress myeloid differentiation genes such as PU.1 [#23, #26, #27, #28].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Established how ligand binding switches the receptor on at the structural level, defining the activation mechanism for the whole RAR class.\",\n      \"evidence\": \"2.0 Å crystal structure of the RA-bound RARγ LBD revealing the 'mouse trap' AF-2 helix repositioning\",\n      \"pmids\": [\"7501014\", \"9016769\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of the full-length heterodimer on DNA not resolved\", \"Does not capture corepressor- or coactivator-bound conformations\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Showed RARγ acts on RAREs as an RXR heterodimer and is itself autoregulated, anchoring it in the RA transcriptional circuit.\",\n      \"evidence\": \"Reporter assays, RARE mutagenesis, and EMSA of the RARγ2 promoter\",\n      \"pmids\": [\"1320193\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Sp1 cooperativity mechanism not detailed at the protein level\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Defined RARγ as the principal RAR mediating differentiation and a specific subset of RA target genes, distinguishing it functionally from RARα/β.\",\n      \"evidence\": \"RARγ-null F9 cell knockout and isoform-specific rescue with target gene and differentiation readouts\",\n      \"pmids\": [\"7823950\", \"7644503\", \"8524212\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanistic basis for isoform target-gene selectivity not resolved\", \"Partial redundancy with RARα leaves unique substrate set incompletely mapped\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Pinned the differentiation function to the AF-2 helix-12 motif, linking structure to phenotype.\",\n      \"evidence\": \"AF-2 deletion mutants in RARγ-null F9 cells showing dominant-negative block of differentiation\",\n      \"pmids\": [\"10910773\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Coactivators recruited via AF-2 in this context not identified\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Connected receptor activation to phosphorylation and proteasomal turnover, showing transcription and degradation are coupled.\",\n      \"evidence\": \"p38MAPK and proteasome inhibition, SUG-1 Co-IP, AF-1/AF-2 mutagenesis, and pulse-chase in RARγ2\",\n      \"pmids\": [\"12110588\", \"12824162\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase mediating ubiquitination not identified\", \"Quantitative relationship between turnover rate and output undefined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identified vinexin β as a phospho-regulated, RARγ-specific corepressor, explaining how AF-1 phosphorylation derepresses the receptor.\",\n      \"evidence\": \"Yeast two-hybrid, reciprocal Co-IP, colocalization, and gain/loss-of-function reporter assays\",\n      \"pmids\": [\"15734736\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How vinexin β represses transcription mechanistically unclear\", \"Genome-wide targets of this repression not mapped\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Extended RARγ function to adult stem-cell biology, showing it maintains hematopoietic stem cell self-renewal.\",\n      \"evidence\": \"RARγ knockout mice, retroviral overexpression, and serial transplantation with selective agonists\",\n      \"pmids\": [\"16682494\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcriptional targets governing self-renewal in HSCs not defined\", \"Whether the same epigenetic switch operates in HSCs untested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Revealed RARγ's bimodal epigenetic mechanism: an unliganded H2A.Z/Suz12 repressive state that converts to an H3K9/K14ac active state upon RA.\",\n      \"evidence\": \"ChIP and Co-IP in RARγ-null ES cells across multiple chromatin marks and RA target loci\",\n      \"pmids\": [\"20857416\", \"23264745\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Enzymes depositing/removing H2A.Z and Suz12 in this context not identified\", \"Locus-specific rules for chromatin requirement incompletely defined\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Placed RARγ in vivo as the effector of caudal RA signaling controlling Wnt3a/Fgf8, with developmental epistasis to Cyp26a1.\",\n      \"evidence\": \"Cyp26a1/Rarg double-knockout rescue with in situ hybridization for Wnt3a/Fgf8\",\n      \"pmids\": [\"12588859\", \"11784046\", \"24821986\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs. indirect regulation of Wnt3a/Fgf8 not separated\", \"Corepressor identity sustaining the unliganded repressive state in vivo not defined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Revealed a non-genomic role: cytoplasmic RARγ scaffolds RIP1-initiated TNFR1 death complexes, expanding its function beyond transcription.\",\n      \"evidence\": \"shRNA screen, RARγ knockout, TNFR1-RIP1 Co-IP, subcellular fractionation, and in vivo necroptosis model\",\n      \"pmids\": [\"28871172\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signal that triggers nuclear export not defined\", \"Direct binding interface with RIP1/TNFR1 not mapped\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Linked an RARG coding variant to a human disease phenotype, defining a TOP2B-dependent mechanism of anthracycline cardiotoxicity.\",\n      \"evidence\": \"GWAS with functional reporter validation showing S427L derepresses TOP2B, replicated in three cohorts\",\n      \"pmids\": [\"26237429\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How S427L alters receptor conformation/activity not resolved at this stage\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established causality and mechanism for S427L cardiotoxicity and demonstrated pharmacological rescue.\",\n      \"evidence\": \"CRISPR isogenic hiPSC-CMs, RNA-Seq, DNA damage/ROS assays, in vivo mouse model, and agonist rescue (CD1530)\",\n      \"pmids\": [\"32587261\", \"34525346\", \"35364012\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct RARγ targets driving DNA repair impairment not fully enumerated\", \"Clinical translatability of agonist rescue not established\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Defined the molecular basis of RARG-fusion leukemia: helix 11-12 truncation produces ATRA-unresponsive receptors that recruit HDAC3 to block myeloid differentiation.\",\n      \"evidence\": \"Fusion characterization in patient cohorts, structural analysis, HDAC3 Co-IP, transformation assays, and HDAC inhibitor rescue in vivo\",\n      \"pmids\": [\"25510432\", \"39805830\", \"39805831\", \"39046762\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Allosteric mechanism of helix 11-12 truncation not structurally resolved\", \"Full set of differentiation genes silenced by fusion-HDAC3 not mapped\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showed RARγ restrains tumor-associated inflammation by sequestering TRAF6, with lactylation-driven silencing releasing the brake.\",\n      \"evidence\": \"Reciprocal RARγ-TRAF6 Co-IP, TRAF6 ubiquitination assays, H3K18 lactylation ChIP, and in vivo CRC models\",\n      \"pmids\": [\"38245869\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TRAF6 sequestration is nuclear or cytoplasmic not pinned down\", \"Generality beyond macrophages/CRC untested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated RA transcriptional output is entirely RAR-dependent, formally bounding the receptor family's role.\",\n      \"evidence\": \"CRISPR triple knockout of all three RARs with genome-wide RNA-Seq in ES cells\",\n      \"pmids\": [\"29848550\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not partition the RARγ-specific fraction of the transcriptome\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How RARγ partitions between its genomic (RARE/chromatin) and non-genomic (cytoplasmic scaffold) modes, and which signals govern its nuclear export, remains unresolved.\",\n      \"evidence\": null,\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of cytoplasmic RARγ complexes\", \"Trigger and machinery for nucleocytoplasmic shuttling undefined\", \"Integration of phosphorylation, turnover, and localization into a unified switch unmapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 3, 5, 18, 38]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [3, 32, 33]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [0, 1, 2]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 8]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [21, 25]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [10, 17, 23, 29]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [21, 33]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [17, 18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 4, 18, 38]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [19, 22, 36]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [17, 18]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [21, 35]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [11, 27, 28]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [8, 9]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [25, 34]}\n    ],\n    \"complexes\": [\n      \"RARγ-RXRα heterodimer\",\n      \"RARγ/Suz12 (PRC2-associated) complex\",\n      \"TNFR1-RIP1 death complex (complex II/necrosome)\"\n    ],\n    \"partners\": [\n      \"RXRA\",\n      \"SUG-1\",\n      \"vinexin β\",\n      \"TRAF6\",\n      \"RIP1\",\n      \"HDAC3\",\n      \"CDK1\",\n      \"Suz12\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}